NDA 021732 · Endo Operations
Vantas
Histrelin Acetate · Subcutaneous
DiscontinuedLast checked: Nov 20, 2026Latest source record: May 6, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2004
Oct 12, 2004
Approved uses
1
Original approval plus efficacy supplements
Registered trials
9
7 Phase 3, 2 recruiting
FAERS reports
0
0 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
No structured label for this application in openFDA. Older and discontinued products often have none.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
1 products under this application
- VANTAS · HISTRELIN ACETATE 50MG · IMPLANT, SUBCUTANEOUS · Discontinued
Clinical trials
Interventional ClinicalTrials.gov studies with "Histrelin" as an intervention, any sponsor and status, largest first.
- Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT TrialPivotal-lookingActive, not recruiting
NRG OncologyAcademic, hospital or other
NCT04513717 · 2,753 participants · Start Jan 21, 2021 · Primary completion Dec 31, 2033
Drug: Apalutamide; Bicalutamide and 8 more · For: Prostate Adenocarcinoma; Stage III Prostate Cancer AJCC v8; Stage IVA Prostate Cancer AJCC v8
Sites: Fairbanks, Alaska; Gilbert, Arizona; Peoria, Arizona · 602 sites in all
- Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score, The Guidance TrialPivotal-lookingActive, not recruiting
NRG OncologyAcademic, hospital or other
NCT05050084 · 2,050 participants (planned) · Start Dec 6, 2021 · Primary completion Nov 11, 2026
Drug: Bicalutamide; Buserelin and 8 more · For: Prostate Adenocarcinoma
Sites: Birmingham, Alabama; Gilbert, Arizona; Peoria, Arizona · 576 sites in all
- Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate CancerPivotal-lookingRecruiting
SWOG Cancer Research NetworkResearch network
NCT03678025 · 1,273 participants (planned) · Start Sep 24, 2018 · Primary completion Apr 1, 2033
Drug: Abiraterone; Bicalutamide and 9 more · For: Castration Levels of Testosterone; Metastatic Prostatic Adenocarcinoma; Stage IV Prostate Cancer AJCC v8 and 2 more
Sites: Gilbert, Arizona; Phoenix, Arizona; Scottsdale, Arizona · 338 sites in all
- Stereotactic Body Radiation Therapy Plus Immediate or Delayed Androgen Receptor Pathway Inhibitor and Androgen Deprivation Therapy or Salvage Radiation Therapy for the Treatment of Prostate Cancer, DIVINE TrialPivotal-lookingRecruiting
Mayo ClinicAcademic, hospital or other
NCT06378866 · 532 participants (planned) · Start Jun 3, 2024 · Primary completion Feb 28, 2031
Drug: Abiraterone; Apalutamide and 9 more · For: Recurrent Castration-Sensitive Prostate Carcinoma; Recurrent Prostate Cancer; Castration-resistant Prostate Cancer and 1 more
Sites: Phoenix, Arizona; Jacksonville, Florida; Rochester, Minnesota
- Veterans Affairs Seamless Phase II/III Randomized Trial of STAndard Systemic theRapy With or Without PET-directed Local Therapy for Oligometastatic pRosTate CancerPivotal-lookingActive, not recruiting
VA Office of Research and DevelopmentFederal agency
NCT04787744 · 378 participants · Start Jul 1, 2021 · Primary completion Oct 2, 2026
Drug: Goserelin, Histrelin, Leuprolide & Triptorelin; ADT + Nilutamide, Flutamide, & Bicalutamide and 6 more · For: Prostate Cancer; Oligometastasis; Oligorecurrence and 3 more
Sites: Long Beach, California; West Los Angeles, California; Washington D.C., District of Columbia · 20 sites in all
- Study to Evaluate Efficacy and Safety of Histrelin Subdermal Implant in Men With Advanced Prostate CancerPivotal-lookingCompleted
Endo USA Inc., a Keenova Therapeutics CompanyIndustry
NCT01697384 · 138 participants · Start Apr 2000 · Primary completion Aug 2003
Drug: histrelin acetate · For: Prostate Cancer; Adenocarcinoma of the Prostate
- Study of Histrelin Subdermal Implant in Patients With Prostate CancerPivotal-lookingCompleted
Endo USA Inc., a Keenova Therapeutics CompanyIndustry
NCT01394263 · 59 participants · Start May 2000 · Primary completion Dec 2001
Drug: Histrelin hydrogel implant; Zoladex goserelin implant · For: Prostate Cancer; Adenocarcinoma of the Prostate
- Histrelin Subcutaneous Implant in Children With Central Precocious PubertyPivotal-lookingCompleted
Endo USA Inc., a Keenova Therapeutics CompanyIndustry
NCT00779103 · 36 participants · Start Sep 2004 · Primary completion Aug 2011
Drug: Histrelin Subcutaneous Implant · For: Central Precocious Puberty
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
No FAERS reports name this application.
FAERS reports by year
By the date FDA received the report.
No reports.
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- The histrelin implant: a novel treatment for central precocious puberty.
Hirsch HJ, Gillis D, Strich D, et al. · Pediatrics 2005 · Clinical Trial, Comparative Study
- An evaluation of the pharmacokinetics and pharmacodynamics of the histrelin implant for the palliative treatment of prostate cancer.
Dineen MK, Tierney DS, Kuzma P, et al. · J Clin Pharmacol 2005 · Clinical Trial, Phase III, Multicenter Study
- Efficacy and safety of histrelin subdermal implant in patients with advanced prostate cancer.
Schlegel PN · J Urol 2006 · Clinical Trial, Multicenter Study
- Effective long-term androgen suppression in men with prostate cancer using a hydrogel implant with the GnRH agonist histrelin.
Schlegel PN, Kuzma P, Frick J, et al. · Urology 2001 · Clinical Trial, Research Support, Non-U.S. Gov't
- Comparative Cardiovascular Safety of Gonadotropin-releasing Hormone Antagonists and Agonists Among Patients Diagnosed with Prostate Cancer: A Systematic Review and Meta-analysis of Real-world Evidence Studies.
Patel S, Zhu K, Dave CV, et al. · Eur Urol Oncol 2025 · Systematic Review, Meta-Analysis
- Long-Term Continuous Suppression With Once-Yearly Histrelin Subcutaneous Implants for the Treatment of Central Precocious Puberty: A Final Report of a Phase 3 Multicenter Trial.
Silverman LA, Neely EK, Kletter GB, et al. · J Clin Endocrinol Metab 2015 · Clinical Trial, Phase III, Multicenter Study
Sponsor: Endo Operations
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.